We are pleased to invite investors and analysts to participate in our virtual event on Sunday, 16 June 2024, to discuss Ph III STARGLO results in 2L+ DLBCL presented during the EHA congress and provide an update in non-malignant hematology.   13:00 – 14:00 CEST / 12:00 – 13:00 BST 07:00 – 08:00 am EDT / 04:00 – 05:00 am PDT   The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 12:00 CEST on the day of the event. > click here   Agenda Introduction Bruno Eschli, Head of Investor Relations   STARGLO: Columvi-GemOx for R/R DLBCL - Results of a Global Randomized Ph III Trial Jeremy Abramson, Massachusetts General Hospital Cancer Center, Boston, MA, USA   Roche Bispecific Antibodies in NHL William Waas, Lifecycle Leader NHL Bispecific Program, Global Product Strategy   Hemlibra: Improving Patient Experience Daud Chaudry, Lifecycle Leader Hemlibra Program, Global Product Strategy   Q&A   Access to virtual event (pre-registration required) Please pre-register for our webinar here*.   Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.   A replay of the webcast will be available via > ir.roche.com   *privacy notice     Best regards,
Bruno Eschli Head of Investor Relations	Rishard Salie Investor Relations Officer

Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

get the latest news and updates to your inbox.